Formulated Toothpaste Could Improve Allergic Reactions to Peanut Allergy
The results found that INT301 met both its primary and secondary endpoints and could be a safe and effective option for individuals that experience food allergies.
New study findings announced positive results of a specially formulated toothpaste that could be used for oral mucosal immunotherapy (OMIT) for peanut allergies. Data were presented at the 2023 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting.
Image credit: Tanawut | stock.adobe.com
“OMIT uses a specially formulated toothpaste to deliver allergenic peanut proteins to areas of the oral cavity,” said William Berger, MD, ACAAI member, allergist, and author of the study, in a press release. “OMIT as a delivery mechanism for peanut protein has great potential for food allergy desensitization. Due to its targeted delivery and simple administration, it supports the goal of improved adherence.”
Another form of oral immunotherapy includes consuming a small amount of peanut over time to diminish the reaction if individuals were to inadvertently eat an item that contained peanuts. However, the study authors said OMIT provided an advantage over other immunotherapies because of its “targeted delivery and simplified administration, supporting the goal of improved adherence.”
The researchers conducted the phase 1 OMEGA trial that included 32 individuals 18 to 55 years of age who had a peanut allergy. In a 3:1 ratio, the individuals were randomly assigned to receive either an increased dose of INT301 or the placebo. The individuals needed to fail an oral food challenge that included greater than 100 mg of peanut protein. A positive SPT was also needed, that had a wheal diameter of 3mm greater than control and/or psIgE ≥ 0.35 kU/L, according to study authors.
The trial remained active for a total of 48 weeks. The study authors noted that safety among the increase of dosing, maintenance phases, and exploratory biomarkers were assessed.
The study authors said the results found that INT301 met both its primary and secondary endpoints. OMIT’s results displayed a safe and effective option for individuals that experience food allergies.
“We noted that 100% of those being treated with the toothpaste consistently tolerated the pre-specified protocol highest dose,” said Berger, in a press release. “No moderate nor severe systemic reactions occurred in active participants. Non-systemic adverse reactions were mostly local (oral itching), mild, and transient. There was 97% adherence to treatment with no dropouts due to study medication. OMIT appears to be a safe and convenient option for adults with food allergies. The results support continued development of this toothpaste in the pediatric population.”
Reference
Special toothpaste may lower risk of allergic reactions for adults with peanut allergy. EurekAlert!. News release. November 9, 2023. Accessed December 18, 2023. https://www.eurekalert.org/news-releases/1005905.
